Member Info for Bluetnot

Waiting for the rise !! Time will tell.

Good information

Phase I/II clinical trial in retinitis pigmentosa We have commenced a Phase I/II clinical trial in the US with our human retinal progenitor cell (hRPC) therapy candidate for retinitis pigmentosa (RP). Recap: Waiting for the push.

Its not a good policy to scare mong just so you can get a better price. This company will get bigger. Long term share holders will be rewarded.

Victims of a devastating form of blindness have been given hope by a new stem-cell treatment that rejuvenates the eyes. There is no cure for retinitis pigmentosa, an inherited condition that slowly constricts vision, but a British firm has reported early success with a revolutionary procedure that helps to repair a damaged retina. The treatment involves growing billions of ‘progenitor’ stem cells in a laboratory. These have the ability to transform themselves into other types of cell depending on where they are placed in the body. A million stem cells are injected into the back of the patient’s eyeball. Once there, they transform themselves into new light-sensitive cells called rods and cones which replace those lost prematurely to genetic flaws. Tests on three patients – two men and a woman – who were legally blind produced ‘exciting’ results, according to Olav Hellebo, chief executive of UK biotech firm ReNeuron. Before the procedure, the three could read only the largest group of letters on a special eye test chart, but 18 days after being injected with the cells, their sight had improved to the point where they could read three letter sizes smaller. One patient achieved sufficient progress to no longer be classified as legally blind and another told her doctor that she was able to see the food on her plate for the first time in years. Mr Hellebo told The Mail on Sunday: ‘We are obviously very excited. We have to bear in mind all the caveats – that these are results in only three patients and it is early days – but the reaction from ophthalmologists has been very encouraging.’ The three patients are all American but the development of the technology has been led by experts at ReNeuron in Bridgend, Wales. Nine more patients have been enrolled to test the procedure. Mr Hellebo said the woman, who had been ‘sceptical’ before the procedure, went from being able to see just nine letters on the eye test chart to 29. People are considered legally blind if they can read fewer than 36 letters on the 100-letter chart. ‘She said she could now see the food on her plate, which is really motivating for us to hear,’ he added. The two men improved from nine to 24 letters and from 31 to 45. RP, which affects up to 25,000 people in Britain, is caused by about 100 inherited genetic defects, sometimes alone and sometimes in combination. Loss of vision can begin in childhood, adolescence or adulthood and starts with deteriorating night vision and peripheral vision which gradually narrows so only hazy tunnel vision eventually remains. Total blindness usually ensues.Tina Houlihan, of the Retina UK charity which supports people with inherited sight loss, said: ‘These early results are encouraging and will provide hope to those living with retinitis pigmentosa. However, while the trial is at this very early stage, with only a very small number of

PLC PARTNERS WITH WIRRAL CHAMBER OF COMMERCE 4th February 2019 Inspired Energy plc is pleased to announce a partnership with the Wirral Chamber of Commerce, and has joined the organisation as a new Patron Partner. Inspired Energy plc is one of the UK’s leading energy consultancies, working with corporate and SME businesses to optimise the value of every pound spent on utilities. This is achieved through a range of specialist solutions aimed at lowering bills and protecting businesses against rising energy costs and changes in legislation. The partnership with Wirral Chamber of Commerce reflects Inspired Energy’s strong, on-going commitment of helping Chamber members across the UK access a range of services to help them lower their utilities bills and reduce energy usage. Ben Beetham, Head of Partnerships at Inspired Energy plc, said: “We’re delighted to welcome the Wirral Chamber of Commerce as a new partner. The Chamber plays a pivotal role in the growth and development of Wirral’s economy, driving business growth and competitiveness on both a local and international scale. “We will deliver a range of energy services which will help Wirral Chamber members solve a range of utility cost and carbon challenges. “Regardless of how much energy your business consumes, our team of expert energy experts can provide a bespoke service which meets your specific needs. This will leave you free to focus on running your organisation as profitably and effectively as possible.” Paula Basnett, CEO of Wirral Chamber of Commercecommented, “Wirral Chamber of Commerce is always seeking to work with those organisations which can and will deliver benefits which offer advantages for our membership and the wider business community. We are delighted to have now brought Inspired Energy plc into this valuable Patron section, and we will be working closely with Inspired Energy staff to develop this new partnership.” Wirral Chamber of Commerce is accredited by The British Chambers of Commerce (BCC); a dynamic and independent business network. Accredited Chambers sit at the heart of local business communities, helping thousands of companies – of every size and sector – to grow and thrive.  Wirral Chamber of Commerce has a wide range of industrial and commercial members including Typhoo Tea, Bristol Myers Squibb, Russell Taylor Group, Finsa UK and Liverpool John Lennon Airport. For more information about the partnership, please contact Ben Beetham on 01772 689 250 or email partnerships@inspiredenergy.co.uk

Michael Hunt talks Proactive London's Andrew Scott through a deal they've signed which is potentially worth up to £80mln in success-based payments with an arm of one of China's leading drug companies. Fosun Pharma is licensing the rights to the company’s CTX and hRPC cell therapy programmes in the People’s Republic for an initial £6mln.

Thu, 4th Apr 2019 14:19(Sharecast News) - Cell-based therapeutics developer  ReNeuron Group updated the market on progress with its ongoing phase 1 and 2 clinical trial in the US of its 'hRPC' cell therapy candidate in the blindness-causing disease retinitis pigmentosa (RP) on Thursday, confirming that the positive efficacy seen and previously announced had, to date, been sustained in the first patient cohort in the phase 2 part of the study.  The AIM-traded company had reported in February that all three of the first cohort of subjects in the study had reported a "rapid and significant" improvement in vision, on average equivalent to reading an additional three lines of five letters on the ETDRS eye chart - the standardised eye chart used in clinical trials to measure visual acuity. Last month, it announced that dosing of the second cohort of three phase 2 subjects had begun. That next dose cohort comprised patients who had a greater baseline level of visual acuity than those treated in the study thus far. Further read-outs from the patients treated in the study would be presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit, taking place in Vancouver, Canada on 26 April. ReNeuron said it would make a further announcement later in April, when those further read-outs from the study were known. The company said its RP clinical programme benefited from 'Orphan Drug Designation' in both Europe and the US, as well as 'Fast Track' designation from the FDA.  "We remain greatly encouraged by the continued positive efficacy we are seeing in the ongoing phase 1 and 2 study with our hRPC cell therapy candidate for retinitis pigmentosa," said chief executive officer Olav Hellebø. "We look forward to providing a further update on progress with the study at the time of the Innovation Summit in Vancouver later this month."